Sevonu Liquid 250 mL Volatile liquid
PDF Leaflet Revision Date: 06 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Induction and maintenance of general anaesthesia.
Dosage (summary)
Individualised; inspired concentrations of 0.5-3% for maintenance.
Onset of Action / Duration
Onset: <2 mins, Duration: variable.
Special Populations
- Elderly
- Paediatric
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Caution in pregnancy; not established in lactation.
Key Drug Interactions
- Beta-sympathomimetics
- Calcium antagonists
- Succinylcholine
Contraindications
- Hypersensitivity to sevoflurane
- Malignant hyperthermia
- Neuromuscular disease
Common side effects
- Hypotension
- Nausea
- Vomiting
- Agitation
Counselling Points
- Avoid driving post-anaesthesia
- Monitor for respiratory issues
- Skip breastfeeding for 48 hours post-use
Serious warnings
- Respiratory depression
- Malignant hyperthermia risk
- Hepatic dysfunction
Important Disclaimer
The Sevonu Liquid 250 mL Volatile liquid professional information leaflet below is the property of Lamar International and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
